posted on 2023-04-04, 01:40authored byMcKensie A. Collins, In-Young Jung, Ziran Zhao, Kimberly Apodaca, Weimin Kong, Stefan Lundh, Joseph A. Fraietta, Arnon P. Kater, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst
<p>Supplemental Figure 1: An overview of study design choices. Supplemental Figure 2: IL-2 Supplementation Enhances the APC phenotype of CLL cells. Supplemental Figure 3: Exogenous Co-stimulation Improves Second-generation CAR T cell Activation. Supplemental Figure 4: aCLL Stimulation Shows Inconsistent Cytokine Production After a 6hr Incubation. Supplemental Table 1: Full Antibody List. Supplemental Table 2: CLL Donor List. Supplemental Table 3: Full list of adjusted P-values from Holm-Sidak multiple comparisons.</p>
Funding
Parker Institute for Cancer Immunotherapy (Parker Institute)
CLL cells insufficiently activate CAR T cells, driven by low levels of costimulatory molecules on the tumor. LN-derived CLL cells are more costimulatory and mediate enhanced CAR T-cell killing. This costimulatory phenotype can be modeled via CD40 L activation, and the activated tumor promotes stronger CAR T-cell responses.